Heidelberg Pharma AG’s Post

DCRI's Jennifer Rymer and Schuyler Jones, along with former DCRI member Sunil Rao, joined their colleagues at #ACC24 this morning for a deep dive into the ACS toolbox, where they examined guidelines, proven and potential therapies, and opportunities to tailor approaches to each patient's unique characteristics and needs. Jones took the opportunity to reinforce GDMT adherence after ACS and noted 30% of patients still don't receive the Big 5 (aspirin, beta blockers, ACE inhibitors, statins, P2Y12 inhibitors). #clinicaltrials #clinicalresearch #hearthealth #heartdisease

What does #FDA guidance say about CAR T #clinicaltrials? Find out what regulatory guidance means for your study planning and conduct in Advarra's recent white paper:

We’ll be at #ACMG in Toronto next week. Drop by our booth to see how you could be using VarSome Clinical to help you work through cases efficiently. Here’s some of what we’ll be showing: ✅Advanced filters for different cases such as phenotype-driven analysis ✅Family trio analysis filters for identifying de novo mutations and compound heterozygous variants ✅Carrier risk screening ✅Our state of the art Sample View allowing you to visualize all variants in your sample using a fast, efficient, and user-friendly interface ✅How to build customized workflows to set fixed analytical options for your team’s analyses

The #EndTB Strategy prioritizes early TB diagnosis & universal Drug Susceptibility Testing (DST), necessitating a strong lab network. This approach aims to: ➡️Increase access to rapid & accurate TB detection ➡️Reach universal access to DST ➡️Strengthen the quality of lab services

We're excited to share our new slide deck covering the most recent developments and key timelines for PFAS-related personal injury cases. With the resolution of water contamination cases, the focus is now on Tier 1 injury cases such as kidney and testicular cancer. 🔍 What's Inside: • Bellwether trial schedule and key dates • Strategic focus for legal teams • Important deadlines for expert reports and Daubert motions • Broader context and recent regulatory updates 📅 Key Dates to Watch: • Discovery completion for kidney and testicular cancer cases: June 18, 2024 • Case selections for trial: July 16, 2024 • Fact discovery for thyroid and ulcerative colitis: October 16, 2024 • Daubert Motions briefing completion: April 17, 2025 Stay informed and prepare for the upcoming milestones in PFAS litigation. #PFAS #MassTort #LitigationUpdate #BlueSkyLegal

Will you be at #ARVO2024? Let’s connect!   Join me for one of the many poster presentations featuring new and updated data demonstrating the potential efficacy of our lead drug candidate for Meibomian Gland Dysfunction (MGD). Session details are in the link below. 

REGENXBIO has completed enrollment at the second dose level of the Phase I/II AFFINITY DUCHENNE trial in patients ages 4 to 11 years old with #Duchenne #musculardystrophy. They have reported positive interim safety and efficacy data: https://bit.ly/48dvwAC.

🚀 Exciting News! The Pharmacotherapy in Emergencies on-demand program is now fully available on Xpeer! 🏥 Accredited content by UEMS - EACCME in partnership with SEMES and SEFH. With 12 current topics, delivered by leading opinion leaders in the field of pharmacotherapy, it's a unique opportunity to expand your knowledge and skills. Highlighted topics include pneumonia management, sepsis code, drug administration in emergencies, non-atrial fibrillation arrhythmia, among others. ✨Available with Xpeer Premium subscription https://lnkd.in/grsWmGHm #Pharmacotherapy #Emergencies #MedicalEsducation

Top-line data from the recently completed phase 2b RESTORE trial of MCO-010, an investigational #genetherapy for #retinitispigmentosa, show clinically meaningful vision improvement in legally blind individuals. Read more in our current issue. https://lnkd.in/ek72AZv5

Please check this out! If you missed my AAO 2023 presentation of the first time results of the 2 year data from the GATHER2 study, here is a quick summary! Thank you to the Eyetube team, Janet Burk, Julia Hughes, Katherine Quraishi for the opportunity to share this important dataset with the retina community about the continued benefit of every month and every other month avacincaptad pegol (ACP) 2mg for the treatment of GA. Iveric Bio, An Astellas Company #ACP #GA #EM #EOM #clinicaltrials #clinicalresearch